ResearcherCedars-Sinai Medical CenterActive in the last 2 years

Ju Dong Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7834-9825; OpenAlex author ID A5024244120. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 14

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

Automated Resectability Classification of Pancreatic Cancer CT Reports with Privacy-Preserving Open-Weight Large Language Models: A Multicenter Study. Last author DOI 10.1007/s10916-025-02248-2 ↗
Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiot… Co-author DOI 10.3389/fonc.2022.879661 ↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Seo‐Youn Choi · 1 shared paper, 2025 · strength 0.23
- Paper Automated Resectability Classification of Pancreatic Cancer CT Reports with Privacy-Preserving Open-Weight Large Langua… DOI 10.1007/s10916-025-02248-2 ↗
Jisun Lee · 1 shared paper, 2025 · strength 0.23
- Paper Automated Resectability Classification of Pancreatic Cancer CT Reports with Privacy-Preserving Open-Weight Large Langua… DOI 10.1007/s10916-025-02248-2 ↗
Jeong Hyun Lee · 1 shared paper, 2025 · strength 0.23
- Paper Automated Resectability Classification of Pancreatic Cancer CT Reports with Privacy-Preserving Open-Weight Large Langua… DOI 10.1007/s10916-025-02248-2 ↗
Jeong Ah Hwang · 1 shared paper, 2025 · strength 0.23
- Paper Automated Resectability Classification of Pancreatic Cancer CT Reports with Privacy-Preserving Open-Weight Large Langua… DOI 10.1007/s10916-025-02248-2 ↗
Ji Hye Min · 1 shared paper, 2025 · strength 0.23
- Paper Automated Resectability Classification of Pancreatic Cancer CT Reports with Privacy-Preserving Open-Weight Large Langua… DOI 10.1007/s10916-025-02248-2 ↗
Linxi Zhu · 1 shared paper, 2022 · strength 0.12
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661 ↗
Changchang Lu · 1 shared paper, 2022 · strength 0.12
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661 ↗
Lei Wang · 1 shared paper, 2022 · strength 0.12
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661 ↗
Yudong Qiu · 1 shared paper, 2022 · strength 0.12
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661 ↗
Xin Qiu · 1 shared paper, 2022 · strength 0.12
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661 ↗
Qi Li · 1 shared paper, 2022 · strength 0.12
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661 ↗
Juan Du · 1 shared paper, 2022 · strength 0.12
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661 ↗
Jun Chen · 1 shared paper, 2022 · strength 0.12
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661 ↗
Baorui Liu · 1 shared paper, 2022 · strength 0.12
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.